Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 3Interventional 2

Sponsor

Cancer Type

Gastrointestinal 8Genitourinary 7Other hematologic neoplasm 6Lymphoid 5Breast 4Head & Neck 3Thoracic 2Sarcoma 2Plasma cell 2Other solid neoplasm 2Myeloid 2Gynecologic 2Dermatologic 2CNS 1

Conditions

Carcinoma, Ovarian Epithelial 2Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Brenner Tumor 1

Interventions

Paclitaxel 575Carboplatin 520Cisplatin 347Bevacizumab 252pembrolizumab 226Gemcitabine 157Topotecan 128liposomal doxorubicin 127Cyclophosphamide 126olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 80niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 56Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Reverse Transcriptase Polymerase Chain Reaction × Gynecologic × Clear all
NCT00408590 2024-01-16

Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Mayo Clinic

Phase 1 Completed
37 enrolled 8 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Brenner Tumor, Ovarian Neoplasms

NCT01673217 2022-08-01

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Roswell Park Cancer Institute

Phase 1 Completed
18 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡